We held our Autumn Shareholder Reception at Calla Lily Clinical Care’s London HQ yesterday with shareholders, advisors and our team all in one room, and with a good deal to report.

Approaching completion of our FREEDOM clinical trial for Callavid®. A new second use case funded by Wellcome Leap, taking our drug delivery platform into recurrent UTI and antimicrobial resistance. Strategic interest across several of our indications. And a growing recognition of our position among the people setting the agenda in women’s health.

It was also a chance to restate what we won’t compromise on: our standards, our approach, and the reasons we started in the first place.

It’s been over a year since our last reception as work got in the way (which is the right problem to have!) But Lara and I still don’t know many startups that bring their shareholders into the building at all. We do it because women’s health is hard enough that no company ever gets far on its own. What progress there is depends on people willing to put their support, their energy and their belief behind it… as ours do. Thank you! 💛💪